Figure 1.

Evolution of Treatment in AL Amyloidosis

The timeline outlines in chronological order the clinical use of distinct treatments in immunoglobulin light chain (AL) amyloidosis. Commonly used agents/regimens are in red boxes, less commonly used agents/regimens are in green boxes. The top of the figure outlines some of the most impactful technological/clinical advances in AL amyloidosis. ASCT = autologous stem cell transplant; CyBorD = cyclophosphamide-bortezomib-dexamethasone; Dara = daratumumab; Dex = dexamethasone; FLC = free light chain; LC-MS = liquid chromatography-mass spectrometry; MALDI-TOF = matrix-assisted laser desorption ionization time-of-flight; Mel = melphalan; MM = multiple myeloma; MRD = minimal residual disease; NSG = next generation sequencing; Pred = prednisone.